Analysis of Lijun International (01355.HK) Acquiring a Synthetic Biology Company and Undergoing Transformation

Lijun International (01355.HK) is a Hong Kong Exchanges-listed company that recently became a hot topic due to its announcement of acquiring a synthetic biology company and planning to rename itself. The company spent HK$22 million to acquire a 37.5% indirect equity stake in Beisheng Bio, which is a synthetic biology infrastructure provider focusing on strain design and fermentation process development [1]. At the same time, the company proposes to change its name to “Bio Systems Engineering Limited”, implying a business transformation into the synthetic biology field [1]. Synthetic biology is a current market hot track involving multiple high-growth areas such as pharmaceuticals, agriculture, and chemicals. This transformation move has attracted investors’ attention to the company’s future development direction. However, due to the inability to obtain public real-time price and trading volume data for this stock (possibly due to extremely low liquidity or temporary suspension), specific price changes and trading volume analysis cannot be provided.

1. The company is transforming from its original business to the synthetic biology field, attempting to achieve business breakthroughs by leveraging the high growth potential of the synthetic biology track.
2. The synthetic biology field involves multiple high-growth areas such as pharmaceuticals, agriculture, and chemicals, with broad market prospects.
3. The company’s renaming plan reflects its determination to transform, which may help enhance market awareness of its transformation.

• Opportunities
  : The high growth potential of the synthetic biology track provides the company with business development opportunities; if the transformation is successful, it may bring significant growth.
• Risks
  :
  1. Liquidity Risk
     : The stock may have insufficient liquidity, leading to large price fluctuations.
  2. Transformation Risk
     : The company’s transformation from its original business to the synthetic biology field involves uncertainties in technology, market, management, and other aspects.
  3. Valuation Risk
     : Currently, there is no public financial data available to assess the company’s reasonable valuation.

Lijun International (01355.HK) has acquired a synthetic biology company and plans to transform, attracting market attention to its future development direction. The synthetic biology track has high growth potential, but the company faces risks such as liquidity, transformation, and valuation. Since no public real-time price and trading volume data can be obtained, investors need to evaluate carefully.